Incidence, risk factors and outcome of acute kidney injury (AKI) in patients with COVID-19.

BACKGROUND: Acute kidney injury (AKI) is a severe complication of coronavirus disease-2019 (COVID-19). This study aims to evaluate incidence, risk factors and case-fatality rate of AKI in patients with COVID-19.
METHODS: We reviewed the health medical records of 307 consecutive patients with COVID-19 hospitalized at the University Hospital of Modena, Italy.
RESULTS: AKI was diagnosed in 69 out of 307 (22.4%) COVID-19 patients. Stages 1, 2, or 3 AKI accounted for 57.9%, 24.6% and 17.3%, respectively. AKI patients had a mean age of 74.7 ± 9.9 years. These patients showed higher serum levels of the main markers of inflammation and higher rate of severe pneumonia than non-AKI patients. Kidney injury was associated with a higher rate of urinary abnormalities including proteinuria (0.44 ± 0.85 vs 0.18 ± 0.29 mg/mg; P =  < 0.0001) and microscopic hematuria (P = 0.032) compared to non-AKI patients. Hemodialysis was performed in 7.2% of the subjects and 33.3% of the survivors did not recover kidney function after AKI. Risk factors for kidney injury were age, male sex, CKD and higher non-renal SOFA score. Patients with AKI had a mortality rate of 56.5%. Adjusted Cox regression analysis revealed that COVID-19-associated AKI was independently associated with in-hospital death (hazard ratio [HR] = 4.82; CI 95%, 1.36-17.08) compared to non-AKI patients.
CONCLUSION: AKI was a common and harmful consequence of COVID-19. It manifested with urinary abnormalities (proteinuria, microscopic hematuria) and conferred an increased risk for death. Given the well-known short-term sequelae of AKI, prevention of kidney injury is imperative in this vulnerable cohort of patients.

Introduction

COVID-19 is a complex infectious disease characterized by a broad spectrum of manifestations ranging from asymptomatic to severe illness [1]. The disease is associated with a high rate of morbidity and mortality in patients hospitalized for severe symptoms of SARS-CoV-2 pneumonia [2]. Lung is the main target of the virus, but other organs including brain, liver and kidneys can be involved in this infection [3]. The pathogenesis of COVID-19 is poorly understood and the principal etiology of organ dysfunction seems due to the direct and indirect effects of proinflammatory cytokines release [4-6].

The rate of acute kidney injury (AKI) in COVID-19 is unclear, but recent evidence has established that kidney involvement is proportional to the severity of the underlying lung involvement [7]. Studies conducted in China and the US reported a high prevalence of urinary abnormalities (proteinuria and microscopic hematuria) and a rate of AKI ranging from 0.5% to 36.6% [7-13]. A report from Bordeaux (France) documented that the impact of AKI has been estimated to about 80% in severely ill patients admitted in ICU [14].

The etiological mechanism leading to kidney injury is still unknown. Direct cytopathologic damage, cytokine storm/sepsis, drug toxicity and dehydration may be potential interlinked mechanisms of kidney injury in COVID-19 patients. A great number of living and post-mortem kidney biopsies showed a widespread proximal tubule injury consistent with acute tubular necrosis [15-17]. Collapsing glomerulopathy and thrombotic microangiopathy were other common findings on kidney biopsy [16, 18]. The use of offending agents including nonsteroidal anti-inflammatory drugs [19] and high-dose vitamin C [20] has been associated with kidney involvement. Lastly, the detection of the virus in renal parenchyma and consequently in urine leads to hypothesize a potential cytopathic effect of the virus [21], though the pathogenetic mechanism of SARS-CoV-2-driven kidney injury remains elusive. Based on these data, understanding the impact of SARS-CoV-2 infection on kidney function is necessary to elucidate epidemiological and clinical characteristics of patients experiencing AKI. The aim of this study was to evaluate the incidence, risk factors and outcome of AKI in COVID-19 patients.

Methods

Study design and setting

This retrospective, observational study was conducted in patients with laboratory confirmed-COVID-19 admitted to the University Hospital of Modena. The city of Modena is geographically located in Emilia Romagna region that overall accounted for a total amount of 28.143 documented COVID-19 cases on June 18, 2020 [22]. Clinical and laboratory data were prospectively recorded in consecutively admitted patients from 23 February to 27 April 2020. This time frame coincided with the observational period of the study.

The study was approved by the regional ethical committee of Emilia Romagna (prot. n. 0013376/20).

Population

This study recruited all consecutive adult patients (≥ 18 years) admitted with SARS-CoV-2 infection. Patients with chronic kidney disease (CKD) in renal replacement therapy were excluded from the analysis. According to the WHO guidelines, the diagnosis of SARS-CoV-2 infection was defined as a positive real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay of nasopharyngeal swabs or lower respiratory tract specimens. [23].

Standard of care

Delivery of healthcare services for all SARS-CoV-2 infected patients was ensured by a public healthcare system. Care of COVID-19 patients was delivered by an integrated multidisciplinary team including infectious disease specialists, pneumologists, internal medicine physicians, nephrologists, rheumatologists, intensive care and coagulation specialists. Patients were admitted on general and infectious disease ward.

According to the Italian Society of Infectious Diseases’ Guidelines (SIMIT) [24] and recent data on the treatment of COVID-19 [25, 26], all patients received standard of care treatment including:

(a) oxygen supply to achieve a target oxygen saturation (SO2) ≥ 90%; (b) hydroxychloroquine (400 mg BID on day 1 followed by 200 mg BID on days 2 to 5); (c) azithromycin (500 mg QD for 5 days); (d) darunavir/cobicistat (800/150 mg QD) for 14 days; (e) low-molecular weight heparin for prophylaxis of deep vein thrombosis.

From 18 March 2020, combined therapy darunavir/cobicistat was stopped due to the supervening information on the lack of clinical benefit of protease inhibitors (e.g., lopinavir) to treat COVID-19 [27]. A sub-cohort of patients received tocilizumab treatment in addition to the standard of care when they met the following criteria: SO2 < 92% and a PaO2/FiO2 < 200 mmHg in room air or a decrease in PaO2/FiO2 > 30% in the previous 24 h after hospitalization.

Severely ill patients were evaluated by intensive care consultants for ICU admission and invasive mechanical ventilation eligibility. Medical history, age, comorbidities, vital signs, physical and laboratory examinations were assessed daily.

Criteria and definition

AKI was defined according to the 2012 Kidney Disease: Improving Global Outcomes (KDIGO) criteria [28]. Three AKI stages were classified as follows:

(i) stage 1: increase in serum creatinine (sCr) ≥ 0.3 mg/dl within 48 h or 1.5–1.9 times increase of baseline sCr measured within 7 days; (ii) stage 2: 2–2.9 times increase of baseline sCr measured within 7 days; (iii) stage 3: 3 times or greater increase in baseline sCr measured within 7 days or sCr ≥ 4 mg/dl within 48 h or the initiation of renal replacement therapy [28]. Stage of AKI was the highest stage reached during hospitalization. Urine output criteria was not used for the diagnosis of AKI.

Baseline sCr was defined as the last available sCr measurement within 365 days before the onset of COVID-19 symptoms. When not available prior to the diagnosis of COVID-19, sCr measured on admission was used as the ‘baseline’ value.

The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation [29].

Polypharmacy occured when five or more medications were used [30].

Non-renal SOFA score was calculated by subtracting the score resulting from the degree of renal dysfunction from total score [31].

Requirements for admission to the ICU were: (i) hypoxia despite noninvasive ventilatory support; (ii) hemodynamic instability; (iii) cardiac arrest; (iv) respiratory arrest; (v) multiorgan failure.

Data collection

Data collected from electronic medical records included demographics, comorbidities, medications, laboratory values, vital signs and outcomes. They were prospectively recorded from hospital admission. Comorbidities were identified upon review of the patient’s medical records. International Classification of Diseases (ICD) was used to code and classify mortality data from death certificates.

Outcome

The primary outcome measure was the incidence of AKI in hospitalized patients with COVID-19. Additional analyses included the detection of risk factors for AKI and its relationship with mortality.

Statistical analysis

Baseline characteristics were analyzed using descriptive statistics and were reported as proportions, mean (standard deviation [SD]) or median (interquartile range [IQR]) as appropriate. χ2 test or Fisher’s test was used to analyze categorical variables. Analyses of continuous variables were compared using an unpaired t-test or Kruskal–Wallis test, as appropriate. ANOVA has been used to evaluate the differences between AKI stages. A gamma distribution function was used to plot the probability of AKI events during hospitalization.

Mortality and incidence of AKI were evaluated using Kaplan–Meier (K-M) curves. Univariate and multivariate analysis were performed by Cox regression to identify risk factors for AKI. Cox regression also assessed the association between AKI and in-hospital mortality, after adjusting for sex, age, CKD, cardiovascular disease (CVD), diabetes, non-renal SOFA score and chronic obstructive pulmonary disease (COPD).

A P value of less than 0.05 was considered statistically significant. SPSS 23®was used for statistical analysis.

Results

Clinical characteristics of patients with AKI

A total of 307 patients were included in the study. During the study period, 22.4% (n = 69) of patients developed AKI. The mean age of patients with AKI was 74.7 ± 9.9 years. sCr was measured 734 times in the AKI group (10.6 times per patient) during the average period of hospitalization lasting 16.7 ± 10.6 days.

Mean baseline sCr in the AKI group was 1.08 ± 0.5 mg/dl, peaking 2.6 ± 1.8 mg/dl after 9.3 ± 7.9 days from admission. Patients with AKI reported a higher level of proteinuria (0.44 ± 0.85 vs 0.18 ± 0.29 mg/mg; P ≤.0001) and hematuria (P = 0.032) compared to patients without AKI. The main markers of organ involvement (BNP, troponin, AST, INR) and systemic inflammatory response (IL-6, C-reactive protein [CRP], ferritin) were significantly higher than non-AKI group (Tables 1 and 2).

Table 1

Demographics and lab examinations of AKI and non-AKI patients

Variable	All patients*	AKI*	No-AKI*	AKI vs. no-AKI*
	(n = 307)	(n = 69)	(n = 238)	P value
Age, years	65.2 ± (14.01)	74.7 ± 9.9	62.4 ± 13.8	< 0.0001
Range	25–94.4	43–94.2	25–94.4
Males, n. (%)	219 (71.3)	55 (79.7)	164 (68.9)	0.096
Race/ethnicity, n. (%)
White	298 (97)	68 (98.5)	230 (96.6)	0.689
Black	7 (2.2)	–	7 (2.9)	0.35
Other	2 (0.6)	1(1.4)	1 (0.4)	0.399
Lab test, mean (± SD)
Hemoglobin, g/l	11,9	11.2 ± 2.1	12.2 ± 1.76	< 0.001
White cells, mm3	9175 ± 3650	11,454 ± 7805	8160 ± 4304	0.542
Platelets, 109/l	264.3 ± 128.7	231.7 ± 122.2	276.2 ± 129	< 0.0001
Glycemia	106 ± 47.8	111.7 ± 47.5	104.1 ± 47.7	0.14
Potassium, mmol/l	4.6 ± 3	4.01 ± 0.6	4.01 ± 3.3	0.991
Sodium, mmol/l	137.6 ± 4	139 ± 5.52	137.2 ± 3.5	< 0.001
Calcium, mg/l	8.5 ± 0.5	8.4 ± 0.578	8.6 ± 0.5	0.873
Albumin, gr/dl	2.9 ± 0.5	2.7 ± 0.49	3.06 ± 0.47	< 0.0001
Urea, mg/dl	59 ± 41.7	87.8 ± 55.3	45.9 ± 24.4	< 0.0001
D-dimer, mg/l	6064.2 ± 7183.6	5090.2 ± 6588	3130 ± 4969	< 0.0001
Alanine amino-transferase, U/l	136.7 ± 827.1	339 ± 161	67.8 ± 78.8	< 0.0001
Bilirubin, mg/l	0.8 ± 0.7	0.99 ± 1.2	0.74 ± 0.58	< 0.001
INR	1.15 ± 0.4	1.33 ± 0.73	1.09 ± 0.16	< 0.0001
Lactate dehydrogenase, U/l	960.8 ± 3173.1	1782.4 ± 6183	679.2 ± 350.7	< 0.0001
Ferritin ng/ml	944.8 ± 684.3	958.6 ± 691.7	914.3 ± 683.3	0.824
CPK, U/I	211.1 ± 687.8	285.2 ± 1071	187.6 ± 507.4	0.008
BNP, pg/ml	129.3 ± 194.6	221.6 ± 273	98.4 ± 148.3	< 0.0001
Troponin, ng/ml	173.3 ± 1239	276.6 ± 1775	77.01 ± 183.7	0.338
IL-6, ng/L	531.1 ± 684.6	784.8 ± 888	444.4 ± 575.3	< 0.0001
C-reactive protein, mg/l	6.78 ± 7.8	6.87 ± 7.9	6.74 ± 7.8	0.737
Kidney function
sCr measurements, n.	2542	734	1808
Number of sCr/pt	8,2	10,6	7,6
Baseline sCr, mg/dl	0.97 ± 0.58	1.08 ± 0.5	0.8 ± 0.2	< 0.0001
Range	0.24–3.78	0.46–3.78	0.24–2.19
eGFR, ml/min	83.6 ± 22.3	69.3 ± 21.8	87.75 ± 20.8	< 0.0001
Range	14.8–147	14.8–111.9	28.5–147
Peak sCr, mg/dl	1.3 ± 1.1	2.6 ± 1.8	0.9 ± 0.2	< 0.0001
Nadir sCr, mg/dl	0.7 ± 0.5	1.1 ± 0.8	0.6 ± 0.2	< 0.0001
Urine protein-to-creatinine ratio, mg/mg	0.27 ± 0.57	0.44 ± 0.88	0.18 ± 0.29	< 0.0001
Spot urine Na+, Eq/L	97.93 ± 58,48	75.11 ± 40.69	80.27 ± 39.64	0.763
Spot urine K+, Eq/L	36.97 ± 20.57	40 ± 15.04	42.24 ± 27.52	0.813
Microscopic hematuria, n. (%)
Absent	99 (32.2)	12 (26.6)	87 (36.5)	0.032
± / +	31 (10)	19 (42.2)	22 (16)	< 0.0001
+ +	14 (4.5)	4 (8.8)	10 (7.2)	0.525
+ + +	11 (3.5)	2 (4.4)	9 (6.5)	0.098
+  +  +  +	17 (5.5)	8 (17.7)	9 (6.5)	0.03

Statistically significant p values are in bold

AKI acute kidney injury, BNP Brain Natriuretic Peptide, CKD chronic kidney disease, CPK creatine phosphokinase, eGFR estimated glomerular filtration rate, IL-6 interleukin-6, INR international normalized ratio, sCr serum creatinine

*Results are expressed as mean ± standard deviation (SD) unless differently indicated

Table 2

Clinical characteristics and outcome of AKI and non-AKI patients

Variable	All patients*	AKI*	Non-AKI*	AKI vs. non-AKI*
	(n = 307)	(n = 69)	(n = 238)	P value
Mean arterial pressure (mmHg)	65.5 ± 9	67.5 ± 9.1	65.0 ± 8.9	0.109
PO2/FiO2	236.11 ± 114	150.4 ± 82.6	250.7 ± 85.2	< 0.0001
SOFA score	2.6 ± 1.5	3.8 ± 1.8	2.31 ± 1.2	< 0.0001
Range	0–9	0–9	0–8
Comorbidities, n. (%)	189 (61.8)	44 (63.7)	145 (60.9)	0.778
COPD	32 (10)	10 (14.4)	18 (7.6)	0.095
Diabetes	54 (17.6)	15 (21.7)	39 (16.4)	0.001
Hypertension	138 (45)	34 (49.2)	104 (43.7)	0.414
CVD#	70 (22.8)	23 (33.3)	47 (19.7)	0.225
Obesity	28 (30.8)	8 (11.5)	20 (8.4)	0.475
CKD (GFR < 60 ml/min), n. (%)	51 (16.6)	26 (37.6)	25 (10.5)	< 0.0001
CKD Stage 3a	33 (10.7)	17 (24.6)	16 (6.7)	< 0.0001
CKD Stage 3b	13 (4.2)	6 (8.6)	7 (2.9)	0.018
CKD Stage 4	4 (1.3)	2 (2.9)	2 (0.8)	< 0.0001
CKD Stage 5	1 (0.3)	1 (1.4)	–	0.224
Polypharmacy (> 5 drugs), n. (%)	175 (57)	44 (63.7)	131 (55)	0.215
Diuretic agent, n. (%)	46 (14.9)	26 (37.6)	20 (8.4)	< 0.0001
Tocilizumab, n. (%)	152 (49.5)	33 (47.8)	111 (46.6)	0.891
Nephrotoxic agents, n. (%)
NSAID	10 (3.3)	3 (4.3)	7 (2.9)	0.699
RAS-blocker	32 (10.4)	5 (7.2)	27 (11.3)	0.38
Nephrotoxic antibiotics	17 (5.5)	7 (10.1)	10 (4.2)	0.722
Darunavir/cobicistat	123 (40)	24 (34.7)	99 (41.5)	0.337
Time from symptoms to admission, days	8 ± 6.65	6.36 ± 5.7	8.51 ± 6.79	0.0461
Time from admission to mechanical ventilation, days	2.11 ± 2.05	2.25 ± 2	2.12 ± 2.24	0.978
Time from admission to AKI, days	5.8 ± 6.3	9.3 ± 7.9	4.6 ± 7.2	< 0.0001
Time from admission to death, days	12.3 ± 7.2	11.8 ± 7.3	13.4 ± 7	0.45
ICU admission, n. (%)	61 (19.8)	24 (34.7)	37 (15.5)	< 0.001
Mechanical ventilation, n. (%)	53 (17.2)	18 (26)	35 (14.7)	0.045
AKI, n. (%)
AKI Stage 1	40 (13)	40 (57.9)	–
AKI Stage 2	17 (5.5)	17 (24.6)	–
AKI Stage 3	12 (3.9)	12 (17.3)	–
Not recovered AKI in survivors, n. (%)	10 (3.9)	45 (33.3)	–
Renal replacement therapy, n. (%)	5 (1.6)	5 (7.2)	–
Hospital length of stay, days	14.8 ± 9.7	16.7 ± 10.6	14.3 ± 9.3	0.07
Range	0–46	1.9–45.8	0.8–46
Currently hospitalized, n. (%)	71 (23.12)	18 (26.08)	53 (22.26)	0.519
Hospital mortality, n. (%)	55 (17.9)	39 (56.5)	16 (6.7)	< 0.0001
Cause of death, n. (%)
ARDS	33 (10.7)	24 (61.5)	9(56.2)	0.767
Sepsis	10 (3.2)	6 (15.3)	4 (25)	0.453
Septic shock	12 (3.9)	9 (23)	3 (18.7)	1

Statistically significant p values are in bold

ARDS acute respiratory distress syndrome, COPD chronic obstructive pulmonary disease, CVD cardiovascular disease, NSAID nonsteroidal anti-inflammatory drug, RAS renin-angiotensin system, ICU intensive care unit, SOFA sequential organ failure assessment

#Cardiovascular disease includes heart failure, ischemic heart disease and arrhythmia

*Results are expressed as mean ± standard deviation (SD), unless differently indicated

The rate of mechanical ventilation and ICU admission in AKI group was 26% and 34.7%, respectively. Overall, patients with severe acute respiratory distress syndrome requiring mechanical ventilation had a higher rate of AKI events than non-mechanically ventilated patients (P = 0.045). In particular, the incidence of AKI stage 2 and 3, and unrecovered AKI was higher in patients on mechanical ventilation (Supplementary Table 1).

Stage of AKI

Patients with AKI were stratified according to the 2012 KDIGO guidelines and were distributed as follows: stage 1: 57.9%, stage 2: 24.6%, and stage 3: 17.3%. At the end of follow-up, 33.3% of the survivors did not have a full recovery of their kidney function as prior to admission. Five patients with AKI stage III progressed to dialysis (chronic venous-venous hemodialysis [CVVH] or hemodialysis [HD]) in the intensive care unit (ICU); all five died as a consequence of multiorgan failure (MOF). The main differences between AKI stages are detailed in Supplementary Table 2. Data showed that AKI stage 3 patients had a higher baseline value of CRP and SOFA score and a more severe respiratory distress [Pa02/Fi02, 90 (66–15)] compared to patients with AKI stage 1 and 2. No pre-existent differences in terms of morbidities were observed between these two groups of patients.

As shown in Fig. 1, the cumulative incidence curves show a steep rise in AKI stage 3 events within the first 10–15 days from admission.

Fig. 1

Cumulative incidence of AKI events stratified according to KDIGO stage 1–3 during hospitalization

Observation of the frequency histogram (Fig. 2) and the probability distribution plot (Fig. 3) revealed a peak of AKI events at the timing of hospital admission that decreased gradually up to the end of the follow-up period. A substantial clustering of AKI events was noted before patients’ exitus (Fig. 3B).

Fig. 2

Incidence of AKI events during hospitalization for COVID-19

Fig. 3

Probability of AKI related to hospital admission (A) and death (B). In B, the plot of the probability density function included only non-survivors

Risk factors for AKI

To capture probable causes of AKI (e.g., dehydration, hypotension), patients with kidney injury were subdivided into smaller groups, but analysis of the main lab test examinations, performed at baseline and at diagnosis of kidney injury, did not reveal any clinically significant differences. (Supplementary Table 3).

Univariable Cox regression analysis revealed that age (HR = 1.064; 95% CI, 1.04–1.08), CKD (HR = 2.88; 95% CI, 1.76–4.71) and non-renal sequential organ failure assessment (SOFA) score (> 3 points) (HR = 2.05; 95% CI 1.27–3.30) were statistically significant predictors of AKI. Age over 65 years (HR = 4.24; 95% CI2.23–8.09) and GFR < 45 ml/min (HR = 2.28; CI% 1.31–3.97) were the strongest predictors of kidney injury.

Multivariable analyses showed that non-renal SOFA score (> 3 points) (HR = 1.91; 95% CI,1.17–3.11), age (HR = 1.05; 95% CI, 1.03–1.08), CKD (HR = 2.03; 95% CI, 1.17–3.51) and male sex (HR = 2.62; 95% CI, 1.41–4.84) were independent risk factors for AKI in our cohort of patients (Table 3).

Table 3

Univariate and multivariate Cox Regression analysis to identify predictors of AKI

	Univariate				Multivariate
Variable	HR	CI (95%)		P valuec	HR	CI (95%)		P valuec
Sex
Male	1.64	0.91	2.95	0.100	2.62	1.41	4.84	0.002
Age (1 yr increase)	1.06	1.04	1.08	< 0.0001	1.05	1.03	1.08	<0.0001
≥ 65 years	4.24	2.23	8.09	< 0.0001
< 65 years	0.24	0.12	0.45	< 0.0001
Comorbidity	1.09	0.67	1.78	0.727
Hypertension	1.10	0.69	1.77	0.683
Diabetes	1.24	0.70	2.19	0.470
CVD	1.76	1.06	2.90	0.028
COPD	1.57	0.80	3.08	0.188
Obesity	1.52	0.63	3.68	0.352
CKD	2.88	1.76	4.71	< 0.0001	2.03	1.17	3.51	0.011
GFR < 45 ml/min	2.39	1.19	4.83	0.015
GFR 45–59 ml/min	2.28	1.31	3.97	0.004
Nephrotoxic antibiotic	0.95	0.43	2.12	0.903
RAS-blocker	0.62	0.25	1.53	0.296
NSAID	1.11	0.35	3.54	0.860
Darunavir/Cobicistat	0.97	0.58	1.63	0.914
Polypharmacy	1.01	0.59	1.73	0.974
Tocilizumab	0.77	0.48	1.24	0.278
No-renal SOFA (1-point increase)
Score ≤ 3	0.36	0.21	0.62	< 0.001
Score > 3	2.05	1.27	3.30	0.003	1.91	1.17	3.11	0.009

Statistically significant p values are in bold

CKD chronic kidney disease, COPD chronic obstructive pulmonary disease, CVD cardiovascular disease, NSAID nonsteroidal anti-inflammatory drug, RAS renin-angiotensin system, SOFA sequential organ failure assessment

Patients with AKI had an overall mortality rate of 56.5%. A high mortality rate was detected in patients with AKI stage 2 (82.4%) and 3 (83.3%). The primary causes of death were respiratory failure (61.5%), followed by sepsis (15.3%) and septic shock with MOF (9%). Crude mortality was significantly higher in AKI patients (56% vs 6.7%; P≤0.0001) compared to patients with normal kidney function (Table 2).

K-M curves showed high mortality for all patients with AKI, including AKI stage 1 (log-rank p < 0.0001) (Fig. 4).

Fig. 4

Kaplan–Meyer survival analysis between patients with AKI stage 1–3 and non-AKI

Patients experiencing AKI had an unadjusted HR for death of 7.18 (95% CI, 4.01–12.86).

In a multivariable COX regression analysis that included age, sex, comorbidities (diabetes mellitus, CVD, CKD, COPD and non-renal SOFA, the HR for in-hospital death in patients with AKI was 4.82 (95% CI, 1.36–17.08) and 13.21 (95% CI, 2.92–59.69) in patients with unrecovered kidney function at the end of the follow-up compared to non-AKI (Table 4).

Table 4

Adjusted and unadjusted Cox proportional hazard regression model for death with 95% confidence interval in patients with AKI

	Unadjusted relative hazards of death				Adjusted relative hazards of death*				Adjusted relative hazards of death#
	HR	95% CI		P value	HR	95% CI		P value	HR	95% CI		P value
Non-AKI		1.00				1.00				1.00
AKI	7.184	4.010	12.869	< 0.0001	5.230	2.841	9.630	< 0.0001	4.829	1.365	17.080	0.015
Unrecovered AKI	12.565	6.948	22.724	< 0.0001	10.410	5.354	20.241	< 0.0001	13.21	2.927	59.697	0.001

Statistically significant p values are in bold

CI denotes confidential interval

*Hazard ratio adjusted for age and sex

#Hazard ratio adjusted for age, sex, no-renal SOFA score, chronic kidney disease, cardiovascular disease, diabetes and chronic obstructive pulmonary disease

Discussion

The results of this study confirm the recently published data reporting AKI as a frequent event in COVID-19. In a cohort of 307 patients hospitalized for severe respiratory symptoms due to SARS-CoV-2 infection, AKI complicated the clinical course of 69 (22.4%) patients. In the majority of them (57.9%) AKI was mild (stage 1), whereas AKI stage 2 and 3 accounted for 24.6% and 17.3% of the cases, respectively. As already noted in previous studies, [7, 13] kidney injury was accompanied by a higher burden of urinary abnormalities such as microscopic hematuria and proteinuria compared to patients who did not experience AKI. Renal function was replaced in 7.2% of patients with AKI by continuous renal replacement therapy. The outcome of these patients was poor because all died of refractory septic shock evolving in multiorgan failure. Of note, one-third of survivors did not have complete renal recovery at the end of follow-up.

AKI is a devastating syndrome with a significant impact on morbidity and mortality [32]. Early reports from Chinese cohorts documented a low prevalence of renal involvement [8, 33]. Subsequent observational studies conducted in larger cohorts reported an incidence of AKI ranging from 0.5% to 10.4% [8-13]. A recent study evaluating 5449 patients in the New York metropolitan area confirmed that AKI was a frequent complication of COVID-19 [7] since it was diagnosed in more than one-third of patients. AKI occurred in patients with a high burden of comorbidities and, mainly in patients with respiratory distress requiring mechanical ventilation. We are unable to explain the wide variability in the prevalence of AKI, but different criteria adopted for the definition of AKI, population selection, sCr measurement frequency and timing of hospital admission are all potential determinants of these heterogeneous estimates. In our study, AKI was predominantly diagnosed in symptomatic older patients (74.7 versus 62.4 years) experiencing a more severe infection compared to non-AKI subjects. Patients who developed AKI presented a significantly more severe systemic disease (SOFA score, 3.8 versus 2.3), a high level of the classical biomarkers of systemic inflammation (IL-6, LDH, D-dimer, albumin, platelet count, hemoglobin, ferritin) and impairment of other organs including lung (PO2/FiO2), heart (troponin, BNP) and liver (bilirubin, ALT).

Of interest, an early peak was noted in the timeline of AKI development. Similar to the findings of Hirsch et al. [7], this high number of AKI events, coinciding with admission, imposes a careful management of COVID-19 patients within few hours from admission. Early assessment of basic vital parameters and hemodynamic stabilization of critically ill patients may reduce, as far as possible, the severity of kidney injury. After the first peak, observation of our data showed a substantial clustering of AKI events before death. In this setting, the diagnosis of AKI reflected the severity of COVID-19 that in the most severe cases manifested with multiple organs failure including AKI.

Etiology of COVID-19-associated AKI is not fully understood. Potential triggering factors include hemodynamic disturbance, inflammation and exposure to nephrotoxic agents. A further cause of AKI is kidney tropism of SARS-CoV-2. Recent studies  provided insights into the ability of the virus to target the tubular and glomerular cells of the kidney, especially in critically ill patients. [34, 35]. In the present study, we have no data to prove direct virus damage of renal parenchyma. The incidence of AKI was more frequent among patients with CKD and diabetes mellitus, comorbidities largely known to be associated with an increased vulnerability to kidney injury [36-38]. Analysis of risk factors, showed that non-renal SOFA score, age, male sex and CKD were statistically significant predictors of AKI. According to our findings, age [39], male sex [40], CKD [41] are well-known risk factors for AKI in the general population. SOFA score is a reliable prognostic scoring for critically ill patients with sepsis [42] as well as kidney injury [43-46]. Furthermore, extrarenal SOFA score has been identified as independent predictors for AKI in a cohort of non-COVID-19 critically ill surgical patients. [47] In the setting of SARS-CoV-2 infection, a study conducted on 5216 US veterans provided evidence that older age, male sex and lower baseline eGFR were independent risk factors for AKI during hospitalization. [48] In parallel to our findings, several studies confirmed that age [7, 49, 50], male gender [50, 51], severe COVID-19 (respiratory distress) [52] and CKD [49, 51] were independent risk factors for the development of COVID-19-associated AKI during hospitalization.

The identification of these risk factors may elucidate potential strategies for the prevention of kidney injury, as this event is independently associated with in-hospital mortality. The burden of this association is estimated to confer about five-fold excess risk of mortality in patients with AKI and 13-fold in subjects with unrecovered AKI. Detection of vulnerable patients at risk for AKI, prevention and supportive strategy in patients prone to AKI could improve the prognosis of these patients and prevent long-term consequences [53]. According to national health policies, we suggest implementing home assistance of infected patients to minimize the surge of critically ill patients in already overwhelmed hospitals. Therapeutical strategies providing intravenous hydration in dehydrated patients, avoidance of nephrotoxic agents (NSAIDs) and early withdrawn of offending agents (i.e., diuretics, RAS-blockers) may be beneficial if undertaken before arrival in hospital.

Several limitations of this study should be mentioned, some of which intrinsic to the retrospective nature of the study. A certain number of AKI events may be underdiagnosed because of the unavailability of urinary output and sCr at the time of symptoms onset. As a result, the incidence of AKI may be underestimated in our population, however, this limit also recurs in recently published retrospective studies on AKI [13, 14].

Although the hazard ratio for death has been adjusted for potential demographic and clinical confounding variables, we cannot rule out the effect of other unrecognized cofounders. We used the non-renal SOFA score to avoid collinearity between predictor and outcomes. We are confident that the adjustment of our model for this strong clinical variable reinforced the relationship between AKI and in-hospital mortality. Lastly, the lack of data on the long-term outcome of kidney injury, do not allow to weight the real consequences of AKI in term of morbidity and mortality in a cohort of patients at high risk for CKD.

Conclusion

Acute kidney injury was a frequent complication of COVID-19. In our cohort of hospitalized patients it occured in one-fifth of  the population. AKI was generally diagnosed in symptomatic elderly patients with hypoxemia and a severe systemic inflammatory response to the ongoing infection. Non-renal SOFA (score > 3), age, male sex and CKD were risk factors for AKI in our cohort of patients. Identification of the etiological mechanism of AKI and strategy aimed to prioritize the prevention and early identification of AKI are urgently required, as AKI is an independent predictor of all-cause mortality in COVID-19.

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 45 KB)